M. Andjelkovic et al.

Clinica Chimica Acta 558 (2024) 117909

male/female sex ratio of 0.375 which represents 72.72 % of the general with different hemoglobin subtractions of A1B, F, A1C, and LA1C. The
population, our results show a mean UIBC = 279.667 ug/dl, The Pear- RIs were obtained by using the parametric method and the latent abnor-
son correlation coefficients between UIBC and serum iron, ferritin, mal values exclusion (LAVE) principle was applied on A1C.
hemoglobin, CCMH were -0. 117, -0.521, 0.250, -0.227 respectively,
the area under the curve (AUC) for UIBC as a marker of iron storage Conclusions
was 1. The area under the curve for ferritin was 0.886.
This study established RIs for A1C and other Hb subfractions for
Conclusions healthy adult Saudis. Age was found to be an important source of vari-
ation for most of the parameters including A1C. These findings will
UIBC is a better marker of iron depletion in late anemia. UIBC enhance the understanding and clinical decision-making concerning
appears to be a good marker of iron depletion in iron-deficiency ane- A1C and other hemoglobin subfractions. The elevated upper limit of
mias, but further studies are needed to exploit this parameter in order RIs for A1C reflects the high prevalence of diabetes in the Saudi popula-
to establish UIBC as a parameter for the classification of different tion specially in those with increased age.
anemias.
doi: 10.1016/j.cca.2024.117996
doi: 10.1016/j.cca.2024.117995

P0613
P0612
Comparison of estradiol measurement on cobas E411 and unicell
Establishment of reference interval for Hemoglobin A1C and other DxI800 immunochemistry analyzers
Hemoglobin subfractions for healthy Saudi adults M. Andjelkovic c, M. Stanojevic Pirkovic c, M. Petrovic a, I. Nikolic c,
A. Borai c, I. Kiyoshi b, S. Bahijri a, A. Alsofyani c, M. Elsayid c, M. Kostic d, M. Mitrovic c, M. Bulic b
H. Husain c, S. Boraie c, N. Sanan c, Z. Kalantan c, M.J. Jan c, a
University Clinical Center Kragujevac, Department of Laboratory Diagnos-
M. Gassas c, M. Harbi c, N. Alrowaili d, M. Almohammadi c, H. Zarif c,
tics, Serbia
M. Qurashi c b
University Clinical Center of Serbia, Center for Medical Biochemistry, Serbia
a c
Department of Clinical Biochemistry–Faculty of Medicine- King Abdulaziz University of Kragujevac, Serbia, Faculty of Medical Sciences, Department
University, Jeddah, Saudi Arabia of Medical Biochemistry, Serbia
b d
Faculty of Health Sciences, Yamaguchi University Graduate School of University of Kragujevac, Serbia, Faculty of Medical Sciences, Department
Medicine, Ube, Japan of Pharmacology, Serbia
c
King Abdullah International Medical Research Center (KAIMRC), King
Saud bin Abdulaziz University for Health Sciences (KSAU-HS), King Background-Aim
Abdulaziz Medical City, Ministry of National Guard Health Affairs, Saudi
Arabia The objective of this research was to compare the results of Estradiol
d
Ministry of Health, Jeddah, Saudi Arabia concentrations obtained using two immunochemistry autoanalyzers:
Cobas e411 (Roche Diagnostics GmbH, Mannheim, Germany) and Uni-
Background-Aim Cel DxI® 800 (Beckman Coulter, Brea, CA, USA). Cobas e411 utilized
the Elecsys Estradiol III reagent and employed the electrochemilumines-
The establishment of Reference Intervals (RIs) for Hemoglobin A1C cence immunoassay (ECLIA) methodology. UniCel DxI800 used Access
and other hemoglobin subfractions (A1A, A1B, F, LA1C, A0) is of utmost Sensitive Estradiol reagent, employing the chemiluminescent
importance in screening, diagnosing, and monitoring diabetes and other immunoassay method for determination.
hemoglobin abnormalities through the application of high-pressure liq-
uid chromatography (HPLC) technique. Because there are no locally Methods
established RIs for these parameters, it is essential to establish RIs speci-
fic to the Saudi population to accurately diagnose and monitor diabetic A total of 60 patients’ serum specimens were analyzed on both
individuals and identify abnormal levels in hemoglobin subfractions. instruments. All statistical analyses were conducted using MedCalc ver-
sion 22.017 (MedCalc Software Ltd). The correlation study employed
Methods Spearman’s correlation test, and the comparison of assays utilized Pass-
ing-Bablok regression analysis. The difference in measurements was
As part of the IFCC global multicenter study of laboratory reference assessed by calculating the bias using Bland-Altman plots.
values, a cross-sectional study was conducted in Saudi Arabia. The study
involved recruiting a total of 381 healthy adult subjects (>18 years, Results
BMI 28.3 ± 6 kg/m2). Blood samples were analyzed for A1C, biochem-
ical and other immunoassay parameters. The need for RIs based on sex, Estradiol concentrations measured on Cobas 601 Roche ranged from
age, and BMI was determined using the standard deviation ratio (SDR) 10.0 to 3312 pg/mL (median 405.05, 95 % CI for median 209.77-
through a 3-level nested ANOVA. 599.64), while on DxI8000, they ranged from 12 to 2924.30 pg/mL (me-
dian 409.10, 95 % CI for median 241.67 to 590.92). The results exhib-
Results ited a high correlation (r=0.9556) according to Spearman’s
correlation testing. Bland-Altman analysis (plotting the variances
Based on the threshold of SDR≥0.4, RIs for A1C and other Hb sub- between two paired measurements against their mean) for estradiol
fractions were not partitioned by sex or BMI, but partitioned by age levels demonstrated that more than 95 % of points fell between
(<45 & ≥45 years) for A1C, LA1C, A0 and F. Spearman’s correlation ±1.96 SD of the mean (limits of agreement were between -0.9625 to -
between glucose, insulin, and C-peptide showed a positive association 0.9733). Passing-Bablok analysis on the whole group showed an inter-

39
M. Alqahtani et al. Clinica Chimica Acta 558 (2024) 117909

cept (95 % CI) of -20.0934 (-38.1658 to -4.0664) with a slope (95 % CI) Conclusions
of 1.2049 (1.1142 to 1.2529).
Our study shed light on the promising features of acarbose as an inhi-
bitor of 17®-HSD1, paving the way for significant advancements in
Conclusions pharmacological research and drug development.

The results of this research indicate acceptable agreement between

doi: 10.1016/j.cca.2024.117998
estradiol concentration measurements on the Cobas e411 and UniCel
DxI800 platforms.

doi: 10.1016/j.cca.2024.117997
P0615

Evaluating the utility of using glycated albumin in diagnosing

dysglycemia among Saudis – A pilot study
P0614 M. Alqahtani a,b, A. Sabban c,d, S. Bahijri c,d
Acarbose a promising inhibitor of 17®-hydroxysteroid dehydroge- a
Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz
nase type 1 as a potential candidate for anticancer therapy University, Rabigh, Saudi Arabia
b
E. Sebbar a, D. El Moujtahide a, M. Dalli b, M. Choukri a Food Nutrition Lifestyle, King Fahad Medical Research Center, Jeddah,
a
Saudi Arabia
Faculty of Medicine and Pharmacy of Oujda, Mohammed First University, c
Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz
Morocco University, Jeddah, Saudi Arabia
b
Higher Institute of Nursing Professions and Health Techniques, Oujda d
Saudi Diabetes Study Research Group, King Fahad Medical Research
60000, Morocco Center. Food Nutrition Lifestyle, King Fahad Medical Research Center,
Jeddah, Saudi Arabia
Background-Aim
Background-Aim
The 17®-hydroxysteroid dehydrogenase type 1 (17®-HSD1) is a key
enzyme in synthesis of active estrogens such as estradiol. Dysfunctions of Current methods to detect dysglycemia have serious limitations,
this enzyme are associated with development of numerous pathologies, especially in certain health conditions affecting erythrocyte lifespan.
including breast cancer and endometriosis. Therefore, the development Glycated albumin (GA) can reflect glycemic status and is unaffected
novel candidates to modulate the activity of 17®-HSD1 is a critical area by medical diseases that cause inaccurate glycated hemoglobin (HbA1c)
of study for understanding and treating these pathologies. This is the values. We aimed to assess the possibility of using GA for diabetic
framework of our investigation where we aim to explore the potential screening, diagnosis, and monitoring among Saudis.
role of acarbose as a new inhibitor of 17®-HSD1 enzyme.
Methods
Methods
A total of 132 serum samples from the biobank stored at – 80 °C were
The investigation into the affinity between the tested compounds and included. Sample selection to include a wide range of glycaemic status
the target enzyme 17®-HSD1 was conducted through IGEMDOCK was based on stored data of the measurements of HbA1c, and. Results
molecular simulations. Numerous molecules, including acarbose, of fasting glucose (FPG), 1 hour plasma glucose (1-hPG), serum albumin
estrone (the natural substrate of 17®-HSD1), and known inhibitors of were retrieved from data base. Serum GA was measured by ELISA tech-
17®-HSD1 (CID: 9953823, CID: 21043856, CID: 53324805, CID: nique. Results were converted to % by using an equation. Statistical
76317462, CID: 53494954, and CID: 71455718), were subject to molec- analysis was performed to investigate the utility of using GA as an indi-
ular docking studies to assess their potential as new inhibitors of the tar- cator of glycemic status instead of HbA1c, and the correlation between
get enzyme. The 3D structure of the studied enzyme 17®-HSD1 was GA and HbA1c, FPG, and 1-hPG was calculated. Results were considered
retrieved from the Protein Data Bank (PDB), while the chemical struc- significant at a P value <0.05.
tures of acarbose, estrone, CID: 9953823, CID: 21043856, CID:
53324805, CID: 76317462, CID: 53494954, and CID: 71455718 were Results
obtained from the PubChem database.
Using HbA1c, 36.4 % (n=48) were normoglycemic, 31.8 % (n = 42)
Results prediabetics, and 31.8 % (n = 42) diabetics, covering a range between
4.47- 12.7 %. FPG, and 1-hPG did not agree with HbA1c in identifying
Molecular docking results indicated a significant inhibition of the glycaemic status. GA correlated significantly with HbA1c (r = 0.701,
studied enzyme, as reflected by the high binding affinity of acarbose P<0.001), FBG (r = 0.625, P<0.001). and 1h-PG (r = 0.487,
with 17®-HSD1, surpassing that of other molecules, including estrone P<0.001). Based on HbA1c classification of glycaemic status, means
and the inhibitors of 17®-HSD1 (CID: 9953823, CID: 21043856, CID: ±SD of GA % were significantly higher in prediabetic and diabetic sam-
53324805, CID: 76317462, CID: 53494954, CID: 71455718). ples compared to normoglycemic samples (11.67 ± 2.71)% for normo-
The findings of the current study suggest that the acarbose could be a glycemic samples, (14.2 ± 3.0)% for prediabetic, and (19.9 ± 4.9)%
promising inhibitor of 17®-HSD1. It is important to note that acarbose, for diabetic, P< 0.001). However, there was an overlap in the ranges.
already used in the treatment of type 2 diabetes, could potentially
broaden its therapeutic application as an inhibitor of 17®-HSD1. How- Conclusions
ever, further experiments must be conducted to validate these in silico
results and assess the efficacy and safety of this interaction in a physio- GA correlated well with HbA1c and FPG, hence, can be suggested as
logical context. an additional marker to FPG for diagnosing and monitoring glycaemic

40